Melissa Baird Sells 11,750 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 11,750 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total value of $141,940.00. Following the completion of the sale, the chief operating officer now directly owns 538,932 shares in the company, valued at $6,510,298.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Melissa Baird also recently made the following trade(s):

• On Monday, April 8th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.74, for a total value of $173,209.74.
• On Friday, April 5th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.58, for a total value of $171,329.58.
• On Wednesday, March 6th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The stock was sold at an average price of $13.99, for a total value of $164,396.49.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $11.26 on Friday. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $17.16. The stock’s fifty day moving average is $14.01 and its two-hundred day moving average is $10.25.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 26th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. The company had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The company’s revenue for the quarter was up 47.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.05) earnings per share. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on HIMS shares. Canaccord Genuity Group started coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price target on the stock. SVB Leerink began coverage on Hims & Hers Health in a research note on Monday, February 26th. They set a “market perform” rating and a $10.00 price objective on the stock. Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a research note on Friday, April 26th. Truist Financial boosted their price objective on Hims & Hers Health from $10.00 to $13.00 and gave the stock a “hold” rating in a research note on Tuesday, February 27th. Finally, Canaccord Genuity Group began coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective on the stock. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $14.85.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently modified their holdings of HIMS. Forerunner Ventures Management LLC purchased a new stake in shares of Hims & Hers Health in the 4th quarter valued at $86,836,000. Vanguard Group Inc. raised its holdings in shares of Hims & Hers Health by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after buying an additional 428,671 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Hims & Hers Health by 39.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,272,750 shares of the company’s stock valued at $8,006,000 after buying an additional 357,590 shares during the period. Federated Hermes Inc. raised its holdings in shares of Hims & Hers Health by 38.6% in the 3rd quarter. Federated Hermes Inc. now owns 1,032,452 shares of the company’s stock valued at $6,494,000 after buying an additional 287,552 shares during the period. Finally, Must Asset Management Inc. purchased a new stake in shares of Hims & Hers Health in the 3rd quarter valued at $1,596,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.